VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu and currently employs 54 full-time employees. The company went IPO on 2025-03-21. The firm's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The firm is in the late stage of research and development, and its products are close to commercialization.
02561.HK stock price ended at $33.8 on 金曜日, after dropping 1.80%
On the latest trading day Jan 16, 2026, the stock price of 02561.HK fell by 1.80%, dropping from $34.32 to $33.80. During the session, the stock saw a volatility of 3.69%, with prices oscillating between a daily low of $33.10 and a high of $34.32. On the latest trading day, the trading volume for 02561.HK decreased by 15.4K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 15.6K shares were traded, with a market value of approximately $3.8B.